About this trial
When we get injured, our body naturally tries to heal. In adults, this healing often leads to scars - thick, stiff tissue known as fibrotic tissue. Unlike normal tissue, fibrotic tissue doesn't function properly and can cause serious health problems, depending on the affected organ. Once it forms, fibrosis is usually permanent.
A good example of the fibrosis process is the healing of our skin: after a cut or surgery, the resulting scar is a type of fibrosis. Special cells called fibroblasts are key players in this process.
Our study looks at a drug called verteporfin, which is already approved both in Europe and the U.S. Previous research on mice and human cells suggests it can reduce or even prevent fibrosis.
We are now testing, clinically, histologically and by scRNA-seq, whether injecting verteporfin into the skin during wound healing, specifically after surgical procedures, can prevent thick, rigid scars from forming. Since the skin is easy to observe and sample, it offers a great model for studying this.
Will verteporfin have an impact on how surgical wounds heal? That's what we aim to find out.
Eligibility criteria
Qualifiers
Willing and able to provide informed consent as documented by signature
Age is >/= 18 years and < 56 years (differently said: starting from the 18th birthday to completion of their 55 years)
Indication for a safety margin excision (5 mm laterally) due to melanoma in situ or severe dysplastic nevi previously completely excised
Length of initial scar from 15 mm to 50 mm
Disqualifiers
Clinical adenopathy (cervical, axillar, inguinal) defined as a lymph node of more than 1 cm diameter
Melanoma in situ of lentigo maligna or acral lentiginous type
Head and neck location
Diameter of initial lesion above or equal to 3 cm
Trial design
Treatments tested in this trial
- NaCl (placebo)
- Verteporfin Injection
Treatment groups
Locations
Sponsors and collaborators
Jöri Pünchera
Lead sponsor
University Hospital, Geneva
Sponsor institution
University of Geneva, Switzerland
Collaborator
University Hospital, Geneva
Collaborator